AU2006222044A1 - Defibrotide and/or oligodeoxyribonucleotides for treating angiogenesis-dependent tumors - Google Patents

Defibrotide and/or oligodeoxyribonucleotides for treating angiogenesis-dependent tumors Download PDF

Info

Publication number
AU2006222044A1
AU2006222044A1 AU2006222044A AU2006222044A AU2006222044A1 AU 2006222044 A1 AU2006222044 A1 AU 2006222044A1 AU 2006222044 A AU2006222044 A AU 2006222044A AU 2006222044 A AU2006222044 A AU 2006222044A AU 2006222044 A1 AU2006222044 A1 AU 2006222044A1
Authority
AU
Australia
Prior art keywords
use according
defibrotide
angiogenesis
oligodeoxyribonucleotides
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006222044A
Other languages
English (en)
Inventor
Gunter Eissner
Laura Iris Ferro
Massimo Iacobelli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gentium SRL
Original Assignee
Gentium SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT000336A external-priority patent/ITMI20050336A1/it
Application filed by Gentium SRL filed Critical Gentium SRL
Publication of AU2006222044A1 publication Critical patent/AU2006222044A1/en
Priority to AU2007231651A priority Critical patent/AU2007231651B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2006222044A 2005-03-03 2006-02-27 Defibrotide and/or oligodeoxyribonucleotides for treating angiogenesis-dependent tumors Abandoned AU2006222044A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2007231651A AU2007231651B2 (en) 2005-03-03 2007-10-25 Defibrotide and/or oligodeoxyribonucleotides for treating angiogenesis-dependent tumors

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IT000336A ITMI20050336A1 (it) 2005-03-03 2005-03-03 Formulazione ad attivita' anti-tumorale
ITMI2005A000336 2005-03-03
US73140405P 2005-10-28 2005-10-28
US60/731,404 2005-10-28
PCT/EP2006/060304 WO2006094916A1 (en) 2005-03-03 2006-02-27 Defibrotide and/or oligodeoxyribonucleotides for treating angiogenesis-dependent tumors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2007231651A Division AU2007231651B2 (en) 2005-03-03 2007-10-25 Defibrotide and/or oligodeoxyribonucleotides for treating angiogenesis-dependent tumors

Publications (1)

Publication Number Publication Date
AU2006222044A1 true AU2006222044A1 (en) 2006-09-14

Family

ID=36572331

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2006222044A Abandoned AU2006222044A1 (en) 2005-03-03 2006-02-27 Defibrotide and/or oligodeoxyribonucleotides for treating angiogenesis-dependent tumors
AU2006222045A Ceased AU2006222045B2 (en) 2005-03-03 2006-02-27 Oligodeoxyribonucleotides of 4000-10000 Dalton for treating tumors

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2006222045A Ceased AU2006222045B2 (en) 2005-03-03 2006-02-27 Oligodeoxyribonucleotides of 4000-10000 Dalton for treating tumors

Country Status (9)

Country Link
US (2) US20080194506A1 (enExample)
EP (2) EP1855697A2 (enExample)
JP (2) JP5714203B2 (enExample)
KR (3) KR20070120954A (enExample)
AU (2) AU2006222044A1 (enExample)
CA (2) CA2598613A1 (enExample)
IL (3) IL185182A0 (enExample)
MX (2) MX2007010754A (enExample)
WO (2) WO2006094917A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20031714A1 (it) 2003-09-05 2005-03-06 Gentium Spa Formazioni ad azione antitumorale.
EP1982722A1 (en) * 2007-04-16 2008-10-22 Gentium S.p.A. Use of oligotide for the treatment of renal diseases
EP2103689A1 (en) * 2008-03-19 2009-09-23 Gentium S.p.A. Synthetic phosphodiester oligonucleotides and therapeutical uses thereof
US8187897B2 (en) 2008-08-19 2012-05-29 International Business Machines Corporation Fabricating product chips and die with a feature pattern that contains information relating to the product chip
JP6069209B2 (ja) 2010-11-12 2017-02-01 ジェンティウム ソシエタ ア レスポンサビリタ リミタータ 移植片対宿主病（ｇｖｈｄ）の予防および／または治療に使用するためのデフィブロタイド
ES2660969T5 (es) 2012-06-22 2021-09-03 Gentium S R L Método basado en euglobulina para determinar la actividad biológica de defibrotida
EP3026122A1 (en) 2014-11-27 2016-06-01 Gentium S.p.A. Cellular-based method for determining the potency of defibrotide
EP3661484A1 (en) 2017-08-03 2020-06-10 Jazz Pharmaceuticals Ireland Limited Formulations comprising a nucleic acid in a high concentration
WO2019200251A1 (en) 2018-04-12 2019-10-17 Jazz Pharmaceuticals, Inc. Defibrotide for the prevention and treatment of cytokine release syndrome and neurotoxicity associated with immunodepletion
US20220023533A1 (en) 2018-12-07 2022-01-27 Jazz Phrmaceticals Ireland Limited Subcutaneous delivery of high concentration formulations
US20230190783A1 (en) 2020-02-28 2023-06-22 Jazz Pharmaceuticals Ireland Limited Delivery of low viscosity formulations
WO2022234101A1 (en) 2021-05-06 2022-11-10 Jazz Pharmaceuticals Ireland Limited Defibrotide for the treatment and prevention of acute respiratory distress syndrome

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2154279A1 (de) * 1970-11-03 1972-05-25 Crinos Industria Farmaco Medikamente für das fibrinolytische System
US3899481A (en) * 1970-11-03 1975-08-12 Crinos Industria Farmaco Process for the controlled partial degradation of deoxyribonucleic acid extracted from animal organs
IT1043823B (it) * 1970-11-03 1980-02-29 Prephar Procedimento per l estrazione di acidi nucleici da organi animali
IT1170214B (it) * 1983-09-12 1987-06-03 Crinos Industria Farmaco Composizione farmaceutica per la cura delle arteriopatie periferiche
IT1206341B (it) * 1984-02-16 1989-04-14 Crinos Industria Farmaco Composizione farmaceutica per il trattamento dell'ischemia acuta del miocardio.
US4694134A (en) * 1985-05-28 1987-09-15 Ajax Magnethermic Corporation Apparatus for overheating edges of skelp for the production of compression welded pipe
US5223609A (en) * 1986-04-17 1993-06-29 Crinos Industria Farmacobiologica S.P.A. Process for obtaining chemically defined and reproducible polydeoxyribonucleotides
IT1190313B (it) * 1986-04-17 1988-02-16 Crinos Industria Farmaco Procedimento per l'ottenimento di polidesossiribonucleotidi chimicamente definiti e riproducibili e prodotto farmacologicamente attivo risultante
US5977083A (en) * 1991-08-21 1999-11-02 Burcoglu; Arsinur Method for using polynucleotides, oligonucleotides and derivatives thereof to treat various disease states
US6699985B2 (en) * 1991-08-21 2004-03-02 Arsinur Burcoglu Method of treating HIV infection and related secondary infections thereof
IT1252174B (it) * 1991-12-09 1995-06-05 Crinos Industria Farmaco Oligodesossimibonucleotidi ad attivita' antiischemica e procedimenti per il loro ottenimento
US5578716A (en) * 1993-12-01 1996-11-26 Mcgill University DNA methyltransferase antisense oligonucleotides
EP1202750A4 (en) * 1997-04-28 2002-10-16 Arsinur Burcoglu METHOD FOR THE TREATMENT OF HIV INFECTIONS AND THEIR OPPORTUNISTIC INFECTIONS
EP0985035A2 (en) * 1997-05-30 2000-03-15 McGILL UNIVERSITY Dna methyltransferase genomic sequences and antisense oligonucleotides
DE19740384A1 (de) * 1997-09-08 1999-03-11 Max Delbrueck Centrum Antisense Oligodesoxynukleotide (ODN) gegen Proteinkinase C (PKC)-Isoformen, ihre Verwendung und pharmazeutische Zubereitungen dieser ODN
AU2002353783A1 (en) * 2001-09-24 2003-04-07 The Government Of The United States Of America As Represented By The Secretary Of The Department Of SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE
ITMI20031714A1 (it) * 2003-09-05 2005-03-06 Gentium Spa Formazioni ad azione antitumorale.

Also Published As

Publication number Publication date
JP2008531646A (ja) 2008-08-14
AU2006222045B2 (en) 2011-10-20
MX2007010407A (es) 2007-10-17
US20080194507A1 (en) 2008-08-14
CA2598072A1 (en) 2006-09-14
CA2598072C (en) 2016-05-03
KR20070120954A (ko) 2007-12-26
WO2006094916A1 (en) 2006-09-14
JP5714203B2 (ja) 2015-05-07
KR20070120953A (ko) 2007-12-26
IL185182A0 (en) 2008-01-20
EP1853277A1 (en) 2007-11-14
US20080194506A1 (en) 2008-08-14
JP2008531647A (ja) 2008-08-14
IL185258A0 (en) 2008-02-09
WO2006094917A3 (en) 2006-12-14
WO2006094917A8 (en) 2008-01-31
IL185258A (en) 2010-12-30
AU2006222045A1 (en) 2006-09-14
MX2007010754A (es) 2007-11-07
KR20070121001A (ko) 2007-12-26
WO2006094917A2 (en) 2006-09-14
EP1855697A2 (en) 2007-11-21
CA2598613A1 (en) 2006-09-14
IL185181A0 (en) 2008-01-20

Similar Documents

Publication Publication Date Title
Liu et al. A potential target associated with both cancer and cancer stem cells: a combination therapy for eradication of breast cancer using vinorelbine stealthy liposomes plus parthenolide stealthy liposomes
AU2006222045B2 (en) Oligodeoxyribonucleotides of 4000-10000 Dalton for treating tumors
Liu et al. Hypoxia induced HMGB1 and mitochondrial DNA interactions mediate tumor growth in hepatocellular carcinoma through Toll-like receptor 9
WO2011128115A1 (en) Analogues of etoposide for the treatment of tumours
Hoda et al. Temsirolimus inhibits malignant pleural mesothelioma growth in vitro and in vivo: synergism with chemotherapy
Paz-García et al. Beneficial effect of TLR4 blockade by a specific aptamer antagonist after acute myocardial infarction
Yan et al. Anti-angiogenic and antitumor effects of anlotinib combined with bevacizumab for colorectal cancer
Liu et al. G31P, an antagonist against CXC chemokine receptors 1 and 2, inhibits growth of human prostate cancer cells in nude mice
Hasenstein et al. Efficacy of Tie2 receptor antagonism in angiosarcoma
Zhu et al. CXC motif chemokine receptor type 4 disrupts blood-brain barrier and promotes brain metastasis through activation of the PI3K/AKT pathway in lung cancer
EP1867335B1 (en) Oligodeoxyribonucleotides combined with rapamycin for treating cancer
AU2007231651B2 (en) Defibrotide and/or oligodeoxyribonucleotides for treating angiogenesis-dependent tumors
Luke et al. Advances in the systemic treatment of cutaneous sarcomas
KR20050007455A (ko) 올리고뉴클레오티드를 이용하여 세포 성장을 억제하는 방법
JP2017178943A (ja) 血管新生阻害薬
Wu et al. Ergosta-7, 22-diene-2β, 3α, 9α-triol (EGDT) from Ganoderma lucidum inhibits nasopharyngeal carcinoma cells by blocking EGFR signaling pathway
Thomas An In Vivo Biocompatibility Analysis of A Novel Tissue Regeneration Matrix Using A Pig Model
Chen et al. Comparison of tumor-derived total RNA and cell lysate on antitumor immune activity
Zhang et al. Biomimetic immortalized mesenchymal stem cell-based nanoparticles suppress orthotopic postsurgical glioma via CD73 targeting and chemotherapy
HONG et al. Targeting the LPS-STING axis: neomycin restores STING-mediated anti-tumor immune suppression and inhibits tumor growth
Huang et al. Flavonoids from Millettia Speciosa Champ Inhibit the Migration and Angiogenesis of Prostate Cancer Cells
Srivatsa et al. 257 Role of Epidermal Growth Factor Receptor (EGFR) in Inflammation Induced Colorectal Cancers
Wu et al. 260 Enemy or Friend?–Cancer Cell Death by Epidermal Growth Factor
Park et al. 258 Induction of Fas-mediated Extrinsic Apoptosis, P21WAF1-related G2/M Cell Cycle Arrest and ROS Generation by Costunolide in Estrogen Receptor-negative Breast Cancer Cells, MDA-MB-231
HOU et al. Role of TGF-β1/Smad signaling in angiotensinⅡmediated down-regula-tion of connexin 43

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application